Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH SOLAR
NCT04778046Phase 2Recruiting
- Start
- Nov 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hyperpolarized xenon gas in pulmonary hypertension (PH), interstitial lung disease (ILD), chronic obstructive pulmonary disease (COPD) and 1 more (5 arms). Primary endpoint: Pathology-based 129Xe MRI noninvasive signature of pulmonary vascular remodeling at Day 1. Started Nov 2023; status: recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
pulmonary hypertension (PH)interstitial lung disease (ILD)chronic obstructive pulmonary disease (COPD)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04778046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04778046.